Formulation and characterization of polymeric nanoparticle of Rivastigmine for effective management of Alzheimer's disease

• Egile Nagusiak: Faisal Imam (Egilea), Sayantan Mukhopadhyay (Egilea), Preeti Kothiyal (Egilea), Samiyah Alshehri (Egilea), Khalid Saad Alharbi (Egilea), Muhammad Afzal (Egilea), Muzaffar Iqbal (Egilea), Mohammad Rashid Khan (Egilea), Md. Khalid Anwer (Egilea), Abdulrazaq Ahmed Hattab Alanazi (Egilea), Ali Ghanem Alqahtani (Egilea), Mohammed Abdullah Alhamamah (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2024-05-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Memory loss or dementia is a progressive disorder, and one of its common forms is Alzheimer's disease (AD), effecting mostly middle aged and older adults. In the present study, we developed Rivastigmine (RIV) nanoparticles using poly(lactic-co-glycolic acid) (RIV-loaded PLGA NPs) and polyvinyl...